Holen Sie sich die Stockscreener-App
8.84
0.68%
0.06
Handel nachbörslich:
8.97
0.13
+1.47%
Schlusskurs vom Vortag:
$8.78
Offen:
$8.89
24-Stunden-Volumen:
3.65M
Relative Volume:
4.04
Marktkapitalisierung:
$629.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.44M
KGV:
-9.9259
EPS:
-0.8906
Netto-Cashflow:
$-24.66M
1W Leistung:
-0.23%
1M Leistung:
-10.25%
6M Leistung:
+105.58%
1J Leistung:
+344.22%
1-Tages-Spanne:
$8.625
$9.19
1-Wochen-Bereich:
$8.005
$9.49
52-Wochen-Spanne:
$1.87
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.84 | 625.05M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-09 | Eingeleitet | Mizuho | Outperform |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com
What's going on with Immix Biopharma stock Thursday? - MSN
Immix Biopharma Announces Closing of $150 Mil - Moomoo
Immix Biopharma closes $140.65 million stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma closes $140.65 million stock offering - Investing.com UK
IMMX Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common Stock - Quiver Quantitative
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Biotech Immix Biopharma pulls in $140.65M from new stock sale - Stock Titan
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright - TipRanks
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - Sahm
Immix Biopharma Announces $150 Million Stock Offering to Fund NXC-201 AL Amyloidosis Therapy Development - Minichart
Immix Biopharma Raises $150 Million to Advance NXC-201 - TipRanks
Immix Biopharma (NASDAQ: IMMX) prices $150M common stock sale - Stock Titan
Immix Biopharma (IMMX) to raise ~$140.7M net via 16.78M-share sale - Stock Titan
What's Going On With Immix Biopharma Stock Thursday? - Benzinga
Immix Biopharma Prices $150 Million Stock Offering - Moomoo
Sector Update: Healthcare - Moomoo
Immix Biopharma prices $150 million stock offering at $8.94 - Investing.com
Immix Biopharma Reports 95% Complete Response Rate in AL Amyloidosis Trial - Moomoo
Immix rises after mid-stage trial data for AL amyloidosis therapy - Seeking Alpha
Immix Biopharma Reports Strong Interim NXC-201 Phase 2 Data - TipRanks
Immix Biopharma prices $150 million stock offering at $8.94 By Investing.com - Investing.com Australia
Immix Biopharma announces pricing of $150 million underwritten offering of common stock - marketscreener.com
Immix Biopharma announces 95% complete response rate in interim update from relapsed/refractory AL amyloidosis clinical trial NEXICART-2 - marketscreener.com
Immix Biopharma reports 95% complete response rate in trial - Investing.com
Immix Biopharma Announces Pricing Of $150 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma prices $150M deal to fund NXC-201 work into 2028 - Stock Titan
Immix Biopharma reports 95% complete response rate in trial By Investing.com - Investing.com Canada
Immix Biopharma NEXICART-2 interim: 95% CR rate (19/20) as all MRD-negative patients convert - TradingView
Immix Biopharma Reports 95% Complete Response Rate in NEXICART-2 Trial for AL Amyloidosis Patients - Quiver Quantitative
Immix Biopharma (Nasdaq: IMMX) reports 95% CR in NEXICART-2, plans Phase 3 - Stock Titan
Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2 - marketscreener.com
Should You Sell Immix Biopharma (IMMX) After -2.48% Drop? 2026-05-20Certified Trade Ideas - Newser
Why Is Immix Biopharma, Inc. (IMMX) Stock Down Today? - Meyka
Immix Biopharma (IMMX) Q1 2026 Earnings: $-0.18 EPS Surges Past $-0.21 EstimatesSocial Investment Platform - Newser
Immix Biopharma (IMMX) Declines -1.58% Amid Market Weakness 2026-05-15MA Crossover - newser.com
Janus Henderson (IMMX) reports 4.8M shares, 9.1% stake disclosed - Stock Titan
IMMX Stock Price and Chart — NASDAQ:IMMX - TradingView
Immix Biopharma stock rating maintained at Market Outperform by Citizens - Investing.com Nigeria
Immix Biopharma, Inc. 2026 Q1 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immix Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immix Biopharma (NASDAQ: IMMX) Q1 loss widens but cash at $90.6M - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
What Immix Biopharma (IMMX) is doing that could pay off big later (Bearish Sentiment) 2026-05-07High Interest Stocks - Newser
Number of shareholders of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Immix Biopharma, Inc.Common Stock (NQ: IMMX - FinancialContent
Immix Biopharma Finishes NEXICART-2 Trial Enrollment for Amyloidosis - HarianBasis.co
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? - Insider Monkey
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth - Yahoo Finance
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immix Biopharma Inc-Aktie (IMMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):